CHARGED ALPHA
Stock Analysis
TMO Healthcare Latest YouTube: Q4 2025

Thermo Fisher Scientific

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Library coverage

Episodes tracked
2
Episodes linked
1
Latest video
Q4 2025
Podcast available
Yes
Current price
$469.34
-0.78 (-0.17%)
Trailing / Forward P/E
25.77x
Forward: 17.22x
Market cap / Volume
Volume:
Revenue / Earnings Growth
6.2%
Earnings: 11.3%
Margins
17.9% op
Gross: 40.9% · Net: 15.2%
Balance sheet
1.53x current
Debt / Equity: 82.9
52-week range / Beta
$385.46 - $643.99
Beta: 0.87
Analyst target
$599.19
Upside: 27.7%
Cash / shareholder return
3.17% FCF yield
Dividend yield: 0.37%

Company context

Industry: Diagnostics & Research
Country: United States
Employees:
Price to book: 3.31x
Return on equity: 13.5%
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Price chart

Market context for TMO

Competitive view

TMO vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

Thermo Fisher Scientific latest YouTube video thumbnail YouTube
Thermo Fisher Scientific
TMO
Latest video
Q4 2025
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Intuitive Surgical latest YouTube video thumbnail YouTube
Intuitive Surgical
ISRG
Latest video
Q1 2026
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.
Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Johnson & Johnson latest YouTube video thumbnail YouTube
Johnson & Johnson
JNJ
Latest video
Q1 2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.
Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Market Cap
More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.
TMO
$174.42B
Thermo Fisher Scientific
ISRG
$145.58B
Intuitive Surgical
JNJ
$579.83B
Johnson & Johnson
Trailing P/E
Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.
TMO
25.8x
Thermo Fisher Scientific
ISRG
50.0x
Intuitive Surgical
JNJ
27.9x
Johnson & Johnson
Forward P/E
Forward P/E is often a better read on what investors are paying for the next year of earnings power.
TMO
17.2x
Thermo Fisher Scientific
ISRG
34.9x
Intuitive Surgical
JNJ
18.9x
Johnson & Johnson
Revenue Growth
Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.
TMO
6.2%
Thermo Fisher Scientific
ISRG
23.0%
Intuitive Surgical
JNJ
9.9%
Johnson & Johnson
Earnings Growth
Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.
TMO
11.3%
Thermo Fisher Scientific
ISRG
18.8%
Intuitive Surgical
JNJ
-52.9%
Johnson & Johnson
Operating Margin
Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.
TMO
17.9%
Thermo Fisher Scientific
ISRG
30.9%
Intuitive Surgical
JNJ
27.4%
Johnson & Johnson
Gross Margin
Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.
TMO
40.9%
Thermo Fisher Scientific
ISRG
66.3%
Intuitive Surgical
JNJ
68.0%
Johnson & Johnson
Net Margin
Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.
TMO
15.2%
Thermo Fisher Scientific
ISRG
28.2%
Intuitive Surgical
JNJ
21.8%
Johnson & Johnson
Return on Equity
ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.
TMO
13.5%
Thermo Fisher Scientific
ISRG
17.2%
Intuitive Surgical
JNJ
26.4%
Johnson & Johnson
Free Cash Flow Yield
Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.
TMO
3.2%
Thermo Fisher Scientific
ISRG
1.6%
Intuitive Surgical
JNJ
2.2%
Johnson & Johnson
Debt to Equity
Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.
TMO
82.90x
Thermo Fisher Scientific
ISRG
Intuitive Surgical
JNJ
67.73x
Johnson & Johnson
Current Ratio
A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.
TMO
1.53x
Thermo Fisher Scientific
ISRG
4.61x
Intuitive Surgical
JNJ
1.02x
Johnson & Johnson
Beta
Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.
TMO
0.87
Thermo Fisher Scientific
ISRG
1.45
Intuitive Surgical
JNJ
0.26
Johnson & Johnson
Dividend Yield
Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.
TMO
0.4%
Thermo Fisher Scientific
ISRG
Intuitive Surgical
JNJ
2.2%
Johnson & Johnson
Analyst Upside
Higher analyst upside suggests the Street still sees room between current price and consensus fair value.
TMO
27.7%
Thermo Fisher Scientific
ISRG
37.5%
Intuitive Surgical
JNJ
5.0%
Johnson & Johnson

Episode timeline

Episode archive for TMO

Each row is one earnings episode with every verified platform link available.

Q1 2026
Episode pending
Pending link pending
TMO Q1 2026 earnings analysis
Quarterly earnings-analysis entry for Thermo Fisher Scientific. Use the links on the right to open the video or podcast episode.
No verified episode link yet
Q4 2025
Episode live
Published youtube podcast complete
Charged Alpha | Thermo Fisher Scientific (TMO) | Q4 2025 Earnings Deep Dive — Ep. 109
Quarterly earnings-analysis entry for Thermo Fisher Scientific. Use the links on the right to open the video or podcast episode.